CN106890307A - A kind of Chinese medicine composition with effect for reducing blood fat - Google Patents

A kind of Chinese medicine composition with effect for reducing blood fat Download PDF

Info

Publication number
CN106890307A
CN106890307A CN201710170607.8A CN201710170607A CN106890307A CN 106890307 A CN106890307 A CN 106890307A CN 201710170607 A CN201710170607 A CN 201710170607A CN 106890307 A CN106890307 A CN 106890307A
Authority
CN
China
Prior art keywords
weight portion
chinese medicine
weight portions
medicine composition
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710170607.8A
Other languages
Chinese (zh)
Other versions
CN106890307B (en
Inventor
胡镜清
柏冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTE OF BASIC THEORY CACMS
Original Assignee
INSTITUTE OF BASIC THEORY CACMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTE OF BASIC THEORY CACMS filed Critical INSTITUTE OF BASIC THEORY CACMS
Priority to CN201710170607.8A priority Critical patent/CN106890307B/en
Publication of CN106890307A publication Critical patent/CN106890307A/en
Priority to PCT/CN2018/079652 priority patent/WO2018171585A1/en
Application granted granted Critical
Publication of CN106890307B publication Critical patent/CN106890307B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a kind of Chinese medicine composition with effect for reducing blood fat, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 10 50, the weight portion of pseudo-ginseng 5 20, the weight portion of turmeric 5 20, the weight portion of purple perilla 5 20, the weight portion of rhizoma zingiberis 5 20, the weight portion of red yeast rice 15.Chinese medicine composition of the present invention has clear and definite lipid-lowering effect.

Description

A kind of Chinese medicine composition with effect for reducing blood fat
Technical field
The present invention relates to a kind of Chinese medicine composition, and in particular to a kind of Chinese medicine composition of effect for reducing blood fat, belong to the traditional Chinese medical science Medicine field.
Background technology
With the continuous improvement of people's living standard, the incidence of disease of hyperlipidemia is in obvious ascendant trend, and hyperlipidemia is again It is the key factor for inducing coronary heart disease, artery sclerosis, fatty liver, diabetes, obesity etc..Therefore the drop blood of high effect nontoxic is found Fat medicine has important realistic meaning.
Drug research at present to hyperlipidemia is a lot, and Chinese medicine plays the advantage of uniqueness in this respect：Medicine source is enriched, poison Small side effects, comparitive study is definite, there is various effect for reducing blood fat approach again, can flexibly prescription, suit measures to different persons, so having extensively Wealthy application prospect.Hyperlipidemia is clinically attributed to caused by liver and kidney deficiency, insufficiency of the spleen phlegm wet, qi depression to blood stasis etc. by the traditional Chinese medical science, so treatment Shi Duoyong tonifies the liver and kidney, invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing away heat and loosing the bowels, eliminate indigestion and phlegm medicine, and many Chinese medicines have reduction blood fat to act on, But emphasized particularly on different fields in drug effect, the mechanism of action and approach are also different, the Chinese medicine that number of ways plays comprehensive therapeutic effect is only preferably Lipid-lowering medicine.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition with effect for reducing blood fat.
The purpose of the present invention is achieved by the following technical solution：
A kind of Chinese medicine composition with effect for reducing blood fat, the bulk drug of the Chinese medicine composition includes：The Radix Astragali, pseudo-ginseng, ginger Huang, purple perilla, rhizoma zingiberis, red yeast rice.
Preferably, the raw material composition of the Chinese medicine composition is：Radix Astragali 20-50 weight portions, pseudo-ginseng 5-20 weight portions, turmeric 5-20 weight portions, purple perilla 5-20 weight portions, rhizoma zingiberis 5-20 weight portions, red yeast rice 1-5 weight portions.
It is further preferred that the raw material composition of the Chinese medicine composition is：Radix Astragali 22-45 weight portions, pseudo-ginseng 6-18 weight Part, turmeric 6-18 weight portions, purple perilla 6-18 weight portions, rhizoma zingiberis 6-18 weight portions, red yeast rice 1.5-4.5 weight portions.
Still more preferably, the raw material composition of the Chinese medicine composition is：Radix Astragali 25-40 weight portions, pseudo-ginseng 8-15 weights Amount part, turmeric 8-15 weight portions, purple perilla 8-15 weight portions, rhizoma zingiberis 8-15 weight portions, red yeast rice 2-4 weight portions.
Most preferably, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 30, the weight portion of pseudo-ginseng 10, turmeric 10 Weight portion, the weight portion of purple perilla 10, the weight portion of rhizoma zingiberis 10, the weight portion of red yeast rice 2；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 28, the weight portion of pseudo-ginseng 12, the weight portion of turmeric 9, The weight portion of purple perilla 12, the weight portion of rhizoma zingiberis 9, the weight portion of red yeast rice 3；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 35, the weight portion of pseudo-ginseng 9, the weight portion of turmeric 12, The weight portion of purple perilla 9, the weight portion of rhizoma zingiberis 12, the weight portion of red yeast rice 2.
The Chinese medicine composition can be any form constituted as raw material with above-mentioned Chinese medicine, such as be passed through after the mixing of above-mentioned Chinese medicine The composition that crushing is obtained, or the mixing of above-mentioned Chinese medicine/routinely extracting method extracts the extract for obtaining respectively, or extract enters The active component that one step is obtained by polishing purification technique, can also be the extract/active component further according to routine The conventional oral dosage formulations that preparation process is prepared；
General extraction methods of the present invention include that Soakage extraction, decoction extraction, refluxing extraction, seepage pressure effects, ultrasound are carried Take, steam distillation etc.；Extraction solvent includes water, 20~95% ethanol solutions；The polishing purification technique include water extract-alcohol precipitation, Extraction, silica gel chromatograph post separation, macroreticular resin post separation etc.；The conventional oral dosage formulations include powder, tablet, capsule, Granula, oral liquid, pill etc..
Beyond being fed intake divided by bulk drug in traditional Chinese medicinal composition raw materials of the present invention, can also be using extract (effectively Position) form feed intake, such as Astragalus Root P.E, Notogineng Extract, therefore there is drop blood the present invention further discloses one kind The Chinese medicine composition of fat effect：
A kind of Chinese medicine composition with effect for reducing blood fat, the raw material of the Chinese medicine composition constitutes and is：The Chinese medicine group The raw material of compound is constituted：Astragalus Root P.E 20-50 weight portions, Notogineng Extract 5-20 weight portions, Turmeric P.E 5-20 weights Amount part, extractive of perilla 5-20 weight portions, Rhizoma Zingiberis extract 5-20 weight portions, Red Yeast Rice P.E 1-5 weight portions.
Preferably, the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 22-45 weight portions, Notogineng Extract 6- 18 weight portions, Turmeric P.E 6-18 weight portions, extractive of perilla 6-18 weight portions, Rhizoma Zingiberis extract 6-18 weight portions, red yeast rice Extract 1.5-4.5 weight portions.
It is further preferred that the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 25-40 weight portions, pseudo-ginseng carry Take thing 8-15 weight portions, Turmeric P.E 8-15 weight portions, extractive of perilla 8-15 weight portions, Rhizoma Zingiberis extract 8-15 weight Part, Red Yeast Rice P.E 2-4 weight portions.
Most preferably, the raw material composition of the Chinese medicine composition is：The weight portion of Astragalus Root P.E 30, the weight of Notogineng Extract 10 Amount part, the weight portion of Turmeric P.E 10, the weight portion of extractive of perilla 10, the weight portion of Rhizoma Zingiberis extract 10, the weight of Red Yeast Rice P.E 2 Part；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of Astragalus Root P.E 28, the weight portion of Notogineng Extract 12, The weight portion of Turmeric P.E 9, the weight portion of extractive of perilla 12, the weight portion of Rhizoma Zingiberis extract 9, the weight portion of Red Yeast Rice P.E 3；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of Astragalus Root P.E 35, the weight portion of Notogineng Extract 9, ginger The weight portion of yellow extract 12, the weight portion of extractive of perilla 9, the weight portion of Rhizoma Zingiberis extract 12, the weight portion of Red Yeast Rice P.E 2.
Each extract obtains water after being respectively the water extract of each bulk drug or ethanol solution extract or water extract-alcohol precipitation Extract after extract concentration；Extracting method is this area general extraction methods, and such as Soakage extraction, decoction extraction, backflow is carried Take, seepage pressure effects, ultrasonic extraction, steam distillation etc..
To enable formulation of the present invention to realize, pharmaceutically acceptable auxiliary material, example need to be added when these formulations are prepared Such as：Filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, preservative, matrix etc..Filler includes： Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；Disintegrant includes：Starch, pregelatinated form sediment Powder, microcrystalline cellulose, sodium carboxymethyl starch, PVPP, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl fiber Plain sodium etc.；Lubricant includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc.；Suspending agent includes：Polyethylene Pyrrolidones, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Adhesive includes：Starch slurry, polyvinyl pyrrole Alkanone, hydroxypropyl methyl cellulose etc.；Sweetener includes：Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.；Rectify Taste agent includes：Sweetener and various essence；Preservative includes：Parabens, benzoic acid, Sodium Benzoate, sorbic acid and its esters, Benzalkonium bromide, acetic acid chloroethene are fixed, eucalyptus oil etc.；Matrix includes：PEG6000, PEG4000, insect wax etc..To enable above-mentioned formulation Pharmacy of Chinese materia medica is realized, pharmaceutically acceptable other auxiliary materials (Fan Biting need to be added when these formulations are prepared《Pharmacy of Chinese materia medica》, The auxiliary material that each formulation is recorded in Shanghai Science Press December the 1st edition in 1997).
Used as another aspect of the present invention, the present invention also provides the Chinese medicine composition and is preparing with effect for reducing blood fat Medicine in application.
Each bulk drug of the present invention meets 2015 editions《Chinese Pharmacopoeia》Record.
Radix Astragali invigorating middle warmer and replenishing QI in prescription of the present invention, is monarch drug in a prescription Gu table Tuoli, plays the leading work(of the strong fortune of QI invigorating；Pseudo-ginseng has work The effect of blood regulating blood condition, stagnation resolvation is not hindered just, in turmeric can the promoting flow of qi and blood circulation, outward can dispersing wind and cold damp evil, the two compatibility be minister, promoting blood circulation, Promoting qi circulation and relieving pain；Rhizoma zingiberis invigorating the spleen middle benefit gas, dampness removing lipid-loweringing, purple perilla clearing damp inducing diaphoresis, resolving sputum and stomach, two medicines are altogether adjutant；Make medicine red yeast rice, can Reinforcing spleen to promote digestion.The Radix Astragali in side, strengthens body's immunity, can improve the diseases such as treatment deficiency of vital energy weak.Our compatibility is exquisite, with Huang The medicines such as stilbene, pseudo-ginseng, turmeric, rhizoma zingiberis, purple perilla from phlegm, silt, it is wet, empty start with, quite cut the interpretation of the cause, onset and process of an illness, defence month it is remaining can QI invigorating dampness elimination live.
Chinese medicine composition of the present invention has specific compatibility relationship, and changing compatibility relationship cannot then realize the notable of the prescription Effect.
Pharmacological experiments show that prescription of the present invention has clear and definite lipid-lowering effect, and wherein high dose group Bloodlipid-lowering shows Write better than clinical conventional fat-reducing medicament Effects of Xuezhikang.
Specific embodiment
Embodiment 1
Raw material is constituted：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g.
Embodiment 2
Raw material is constituted：Radix Astragali 28g, pseudo-ginseng 12g, turmeric 9g, purple perilla 12g, rhizoma zingiberis 9g, red yeast rice 3g.
Embodiment 3
Raw material is constituted：Radix Astragali 35g, pseudo-ginseng 9g, turmeric 12g, purple perilla 9g, rhizoma zingiberis 12g, red yeast rice 2g.
Preparation method：Appoint the composition matched described in Example 1~3, add water to cook 2 times, 8 times of amount water are added for the first time, 40min is decocted, second plus 6 times of amount water decoct 30min, and merging filtrate, concentration is obtained final product.
Embodiment 4
Raw material is constituted：Radix Astragali 26g, pseudo-ginseng 14g, turmeric 8g, purple perilla 13g, rhizoma zingiberis 9g, red yeast rice 4g.
Embodiment 5
Raw material is constituted：Radix Astragali 38g, pseudo-ginseng 9g, turmeric 12g, purple perilla 8g, rhizoma zingiberis 14g, red yeast rice 2g.
Embodiment 6
Raw material is constituted：Radix Astragali 42g, pseudo-ginseng 7g, turmeric 16g, purple perilla 7g, rhizoma zingiberis 18g, red yeast rice 1.5g.
Preparation method：Appoint the composition matched described in Example 6~9, plus 70% ethanol solution refluxing extraction 2 times, the Once plus 8 times of amount water, 1.5h is extracted, second plus 6 times of amount water, 1h is extracted, merging filtrate, concentration is obtained final product.
Embodiment 7
Raw material is constituted：Radix Astragali 24g, pseudo-ginseng 17g, turmeric 7g, purple perilla 16g, rhizoma zingiberis 6g, red yeast rice 4.5g.
Embodiment 8
Raw material is constituted：Radix Astragali 22g, pseudo-ginseng 19g, turmeric 5g, purple perilla 20g, rhizoma zingiberis 5g, red yeast rice 4.5g.
Embodiment 9
Raw material is constituted：Radix Astragali 48g, pseudo-ginseng 6g, turmeric 19g, purple perilla 5g, rhizoma zingiberis 19g, red yeast rice 1g.
Preparation method：Appoint the composition matched described in Example 7~9, plus 50% ethanol solution ultrasonic extraction 2 times, the Once plus 8 times of amount water, ultrasonic extraction 40min, second plus 6 times of amount water, ultrasonic extraction 30min, merging filtrate, concentration is obtained final product.
Embodiment 10
Raw material is constituted：Astragalus Root P.E 30g, Notogineng Extract 10g, Turmeric P.E 10g, extractive of perilla 10g, rhizoma zingiberis Extract 10g, Red Yeast Rice P.E 2g.
Embodiment 11
Raw material is constituted：Astragalus Root P.E 28g, Notogineng Extract 12g, Turmeric P.E 9g, extractive of perilla 12g, rhizoma zingiberis Extract 9g, Red Yeast Rice P.E 3g.
Embodiment 12
Raw material is constituted：Astragalus Root P.E 35g, Notogineng Extract 9g, Turmeric P.E 12g, extractive of perilla 9g, rhizoma zingiberis carry Take thing 12g, Red Yeast Rice P.E 2g.
Each extract is respectively the water extract of each bulk drug described in above example 10-12.
Embodiment 13
Raw material is constituted：Astragalus Root P.E 26g, Notogineng Extract 14g, Turmeric P.E 8g, extractive of perilla 13g, rhizoma zingiberis Extract 9g, Red Yeast Rice P.E 4g.
Embodiment 14
Raw material is constituted：Astragalus Root P.E 38g, Notogineng Extract 9g, Turmeric P.E 12g, extractive of perilla 8g, rhizoma zingiberis carry Take thing 14g, Red Yeast Rice P.E 2g.
Embodiment 15
Raw material is constituted：Astragalus Root P.E 42g, Notogineng Extract 7g, Turmeric P.E 16g, extractive of perilla 7g, rhizoma zingiberis carry Take thing 18g, Red Yeast Rice P.E 1.5g.
Each extract described in above example 13-15 is respectively 75% ethanol solution extract of each bulk drug.
Embodiment 16
Raw material is constituted：Astragalus Root P.E 24g, Notogineng Extract 17g, Turmeric P.E 7g, extractive of perilla 16g, rhizoma zingiberis Extract 6g, Red Yeast Rice P.E 4.5g.
Embodiment 17
Raw material is constituted：Astragalus Root P.E 22g, Notogineng Extract 19g, Turmeric P.E 5g, extractive of perilla 20g, rhizoma zingiberis Extract 5g, Red Yeast Rice P.E 4.5g.
Embodiment 18
Raw material is constituted：Astragalus Root P.E 48g, Notogineng Extract 6g, Turmeric P.E 19g, extractive of perilla 5g, rhizoma zingiberis carry Take thing 19g, Red Yeast Rice P.E 1g.
Each extract described in above example 16-18 is respectively 50% ethanol solution extract of each bulk drug.
Effect experimental examples
Experimental example 1
1 experiment material
Experimental agents are 1.：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental agents are 2.：Glutinous rehmannia 15g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental agents are 3.：Radix Astragali 30g, lotus leaf 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental agents are 4.：Radix Astragali 30g, pseudo-ginseng 10g, hawthorn 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Preparation method：Take Experimental agents 1.-composition of the 4. proportioning, add water to cook 2 times, for the first time plus 8 times of amount water, 40min is decocted, second plus 6 times of amount water decoct 30min, and merging filtrate, concentration is obtained final product.
2 experimental techniques
60 SD rats are divided into 6 groups, respectively blank group, model group, Experimental agents 1. -4. group, every group of 10 animals. In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to thing respectively, and blank control group and model group give the distillation of same volume Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, determines T-CHOL (CHO), low-density Lipoprotein (LDL) level.
3 experimental results
The results are shown in Table 1.
The each group animal lipid level of table 1 (N=10)
CHO LDL
Blank group 1.69±0.34 0.45±0.18
Model group 4.23±0.25△ 0.89±0.21△
Experimental agents 1. group 2.54±0.24* 0.49±0.14*
Experimental agents 2. group 3.67±0.43*○ 0.67±0.12*○
Experimental agents 3. group 3.71±0.27*○ 0.75±0.15*○
Experimental agents 4. group 3.52±0.34*○ 0.65±0.24*○
Note：Compare with blank group, △ P ＜ 0.05；Compare with model group, * P ＜ 0.05；1. group compares with Experimental agents, and zero P ＜ 0.05.
Result shows, compares with blank group that model group rats CHO and LDL are significantly raised, and illustrates modeling success.Administration three Zhou Hou, Experimental agents 1. -4. can significantly reduce the CHO and LDL of rat model；And Experimental agents 1. effect is significant better than experiment Medicine 2. -4..
Experimental example 2
1 experiment material
Experimental agents are 1.：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental agents are 2.：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g, cassia seed 10g；
Experimental agents are 3.：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g, prepared RADIX ET RHIZOMA RHEI 10g；
Preparation method：Take Experimental agents 1. -3. state the composition of proportioning, add water to cook 2 times, for the first time plus 8 times of amount water, decoct 40min is boiled, second plus 6 times of amount water decoct 30min, and merging filtrate, concentration is obtained final product.
2 experimental techniques
50 SD rats are divided into 5 groups, respectively blank group, model group, Experimental agents 1. -3. group, every group of 10 animals. In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to thing respectively, and blank control group and model group give the distillation of same volume Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, determines T-CHOL (CHO), low-density Lipoprotein (LDL) level.
3 experimental results
The results are shown in Table 2.
The each group animal lipid level of table 2 (N=10)
CHO LDL
Blank group 1.46±0.34 0.29±0.12
Model group 4.19±0.48△ 1.15±0.25△
Experimental agents 1. group 2.46±0.54* 0.46±0.13*
Experimental agents 2. group 3.67±0.48*○ 0.74±0.21*○
Experimental agents 3. group 3.74±0.61*○ 0.72±0.19*○
Note：Compare with blank group, △ P ＜ 0.05；Compare with model group, * P ＜ 0.05；1. group compares with Experimental agents, and zero P ＜ 0.05.
Result shows, compares with blank group that model group rats CHO and LDL are significantly raised, and illustrates modeling success.Administration three Zhou Hou, Experimental agents 1. -3. can significantly reduce the CHO and LDL of rat model；And Experimental agents 1. effect is significant better than experiment Medicine 2. -3..
Experimental example 3
1 experiment material
Experimental agents are 1.：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental agents are 2.：Radix Astragali 10g, pseudo-ginseng 5g, turmeric 5g, purple perilla 20g, rhizoma zingiberis 20g, red yeast rice 2g；
Experimental agents are 3.：Radix Astragali 10g, pseudo-ginseng 5g, turmeric 5g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 10g；
Preparation method：Take Experimental agents 1. -3. state the composition of proportioning, add water to cook 2 times, for the first time plus 8 times of amount water, decoct 40min is boiled, second plus 6 times of amount water decoct 30min, and merging filtrate, concentration is obtained final product.
2 experimental techniques
50 SD rats are divided into 5 groups, respectively blank group, model group, Experimental agents 1. -3. group, every group of 10 animals. In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to thing respectively, and blank control group and model group give the distillation of same volume Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, determines T-CHOL (CHO), low-density Lipoprotein (LDL) level.
3 experimental results
The results are shown in Table 3.
The each group animal lipid level of table 3 (N=10)
CHO LDL
Blank group 2.01±0.24 0.41±0.10
Model group 4.21±0.46△ 1.12±0.24△
Experimental agents 1. group 2.51±0.24* 0.43±0.23*
Experimental agents 2. group 3.64±0.27*○ 0.82±0.18*○
Experimental agents 3. group 3.71±0.45*○ 0.83±0.24*○
Note：Compare with blank group, △ P ＜ 0.05；Compare with model group, * P ＜ 0.05；1. group compares with Experimental agents, and zero P ＜ 0.05.
Result shows, compares with blank group that model group rats CHO and LDL are significantly raised, and illustrates modeling success.Administration three Zhou Hou, Experimental agents 1. -3. can significantly reduce the CHO and LDL of rat model；And Experimental agents 1. effect is significant better than experiment Medicine 2. -3..
Experimental example 4
1 experiment material
Experimental agents：Radix Astragali 30g, pseudo-ginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Preparation method：Bulk drug is taken in proportion, is added water to cook 2 times, 8 times of amount water are added for the first time, decoct 40min, second Plus 6 times of amount water, 30min is decocted, merging filtrate, concentration is obtained final product.
2 experimental techniques
60 SD rats are divided into 6 groups, the respectively high, medium and low dosage group of blank group, model group, Experimental agents, positive drug Effects of Xuezhikang control group, every group of 10 animals.In addition to blank control group is fed using normal diet, other each group animals use fat high Forage feed.After 7 days, gavage gives corresponding liquid respectively for 4 administration group animals, and wherein high dose group gives 5 times of Clinical practices Dosage, middle dose group give 2.5 times of Clinical practice dosage, low dose group give 1 times of Clinical practice dosage, positive drug Effects of Xuezhikang to 1 times of Clinical practice dosage, blank control group and model group is given to give the distilled water of same volume.Each group animal hydration chlorine after 3 weeks After aldehyde anesthesia, eye socket takes blood, and centrifugation obtains serum, determines T-CHOL (CHO), low-density lipoprotein (LDL) level.
3 experimental results
The results are shown in Table 4.
The each group animal lipid level of table 4 (N=10)
CHO LDL
Blank group 1.97±0.22 0.30±0.06
Model group 4.10±0.70△ 1.01±0.17△
High dose group 2.85±0.45* 0.41±0.12*
Middle dose group 2.91±0.21* 0.52±0.12*
Low dose group 3.21±0.36* 0.58±0.19*
Positive drug group 3.22±0.18*○ 0.57±0.21*○
Note：Compare with blank group, △ P ＜ 0.05；Compare with model group, * P ＜ 0.05；Compare with high dose group, zero P ＜ 0.05
Result shows, present invention determine that prescription there is clear and definite lipid-lowering effect, in, low dose group curative effect and positive drug blood Quite, high dose group Bloodlipid-lowering is significantly better than clinical conventional fat-reducing medicament Effects of Xuezhikang to fat health.

Claims (10)

1. a kind of Chinese medicine composition with effect for reducing blood fat, it is characterised in that the bulk drug of the Chinese medicine composition includes：It is yellow Stilbene, pseudo-ginseng, turmeric, purple perilla, rhizoma zingiberis, red yeast rice.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the raw material composition of the Chinese medicine composition is：The Radix Astragali 10-50 weight portions, pseudo-ginseng 5-20 weight portions, turmeric 5-20 weight portions, purple perilla 5-20 weight portions, rhizoma zingiberis 5-20 weight portions, red yeast rice 1-5 weight portions.
3. Chinese medicine composition as claimed in claim 1, it is characterised in that the raw material composition of the Chinese medicine composition is：The Radix Astragali 12-45 weight portions, pseudo-ginseng 6-18 weight portions, turmeric 6-18 weight portions, purple perilla 6-18 weight portions, rhizoma zingiberis 6-18 weight portions, red yeast rice 1.5-4.5 weight portions；
Or, Radix Astragali 25-40 weight portions, pseudo-ginseng 8-15 weight portions, turmeric 8-15 weight portions, purple perilla 8-15 weight portions, rhizoma zingiberis 8-15 Weight portion, red yeast rice 2-4 weight portions.
4. Chinese medicine composition as claimed in claim 1, it is characterised in that the raw material composition of the Chinese medicine composition is：The Radix Astragali 30 weight portions, the weight portion of pseudo-ginseng 10, the weight portion of turmeric 10, the weight portion of purple perilla 10, the weight portion of rhizoma zingiberis 10, the weight portion of red yeast rice 2；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 28, the weight portion of pseudo-ginseng 12, the weight portion of turmeric 9, purple perilla 12 weight portions, the weight portion of rhizoma zingiberis 9, the weight portion of red yeast rice 3；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of the Radix Astragali 35, the weight portion of pseudo-ginseng 9, the weight portion of turmeric 12, purple perilla 9 Weight portion, the weight portion of rhizoma zingiberis 12, the weight portion of red yeast rice 2.
5. the Chinese medicine composition as described in claim any one of 1-4, it is characterised in that each bulk drug warp of Chinese medicine composition The composition that crushing is obtained, or the mixing of each bulk drug/routinely extracting method extracts the extract for obtaining, or extract warp respectively Cross the active component that polishing purification technique is obtained, or the extract/active component is prepared according to conventional formulation technique Preparation.
6. Chinese medicine composition as claimed in claim 5, it is characterised in that the general extraction methods include Soakage extraction, decoct Boil any one in extraction, refluxing extraction, seepage pressure effects, ultrasonic extraction, steam distillation；Extraction solvent include water or 20~ 95% ethanol solution；The polishing purification technique includes water extract-alcohol precipitation, extraction, silica gel chromatograph post separation and macroporous resin column point From；The preparation includes powder, tablet, capsule, granule, oral liquid or pill.
7. a kind of Chinese medicine composition with effect for reducing blood fat, it is characterised in that the raw material composition of the Chinese medicine composition is：It is yellow Stilbene extract 20-50 weight portions, Notogineng Extract 5-20 weight portions, Turmeric P.E 5-20 weight portions, extractive of perilla 5-20 Weight portion, Rhizoma Zingiberis extract 5-20 weight portions, Red Yeast Rice P.E 1-5 weight portions.
8. Chinese medicine composition as claimed in claim 7, it is characterised in that the raw material composition of the Chinese medicine composition is：The Radix Astragali Extract 22-45 weight portions, Notogineng Extract 6-18 weight portions, Turmeric P.E 6-18 weight portions, extractive of perilla 6-18 weights Amount part, Rhizoma Zingiberis extract 6-18 weight portions, Red Yeast Rice P.E 1.5-4.5 weight portions；
Or, the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 25-40 weight portions, Notogineng Extract 8-15 weight portions, Turmeric P.E 8-15 weight portions, extractive of perilla 8-15 weight portions, Rhizoma Zingiberis extract 8-15 weight portions, Red Yeast Rice P.E 2-4 Weight portion.
9. Chinese medicine composition as claimed in claim 8, it is characterised in that the raw material composition of the Chinese medicine composition is：The Radix Astragali The weight portion of extract 30, the weight portion of Notogineng Extract 10, the weight portion of Turmeric P.E 10, the weight portion of extractive of perilla 10, rhizoma zingiberis The weight portion of extract 10, the weight portion of Red Yeast Rice P.E 2；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of Astragalus Root P.E 28, the weight portion of Notogineng Extract 12, turmeric The weight portion of extract 9, the weight portion of extractive of perilla 12, the weight portion of Rhizoma Zingiberis extract 9, the weight portion of Red Yeast Rice P.E 3；
Or, the raw material composition of the Chinese medicine composition is：The weight portion of Astragalus Root P.E 35, the weight portion of Notogineng Extract 9, turmeric carry Take the weight portion of thing 12, the weight portion of extractive of perilla 9, the weight portion of Rhizoma Zingiberis extract 12, the weight portion of Red Yeast Rice P.E 2.
10. application of the Chinese medicine composition as described in any one of claim 1-4,7-9 in blood lipid-lowering medicine is prepared.
CN201710170607.8A 2017-03-21 2017-03-21 A kind of Chinese medicine composition with effect for reducing blood fat Active CN106890307B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710170607.8A CN106890307B (en) 2017-03-21 2017-03-21 A kind of Chinese medicine composition with effect for reducing blood fat
PCT/CN2018/079652 WO2018171585A1 (en) 2017-03-21 2018-03-20 Chinese medicine composition for lowering blood lipid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710170607.8A CN106890307B (en) 2017-03-21 2017-03-21 A kind of Chinese medicine composition with effect for reducing blood fat

Publications (2)

Publication Number Publication Date
CN106890307A true CN106890307A (en) 2017-06-27
CN106890307B CN106890307B (en) 2018-07-10

Family

ID=59192986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710170607.8A Active CN106890307B (en) 2017-03-21 2017-03-21 A kind of Chinese medicine composition with effect for reducing blood fat

Country Status (2)

Country Link
CN (1) CN106890307B (en)
WO (1) WO2018171585A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297949A (en) * 2008-05-15 2008-11-05 天科仁祥技术（北京）有限责任公司 Chinese medicine for preventing and treating hyperlipemia and preparation thereof
CN103372175A (en) * 2012-04-27 2013-10-30 北京北大维信生物科技有限公司 Pharmaceutical composition as well as preparation method and application thereof
CN105362936A (en) * 2015-11-25 2016-03-02 天津天狮生物发展有限公司 Composition capable of assisting blood lipid reducing and preparation method of composition
CN105641509A (en) * 2016-01-14 2016-06-08 吕海峰 Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application
CN106309551A (en) * 2015-07-03 2017-01-11 华北制药秦皇岛有限公司 Perilla seed compound preparation and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1486730A (en) * 2003-07-24 2004-04-07 上海绿谷（集团）有限公司 Capsule prepn for regulating blood fat and blood pressure
CN105433260A (en) * 2015-11-12 2016-03-30 北京至御科技有限公司 Health-care food for reducing blood fat and preparation process thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101297949A (en) * 2008-05-15 2008-11-05 天科仁祥技术（北京）有限责任公司 Chinese medicine for preventing and treating hyperlipemia and preparation thereof
CN103372175A (en) * 2012-04-27 2013-10-30 北京北大维信生物科技有限公司 Pharmaceutical composition as well as preparation method and application thereof
CN106309551A (en) * 2015-07-03 2017-01-11 华北制药秦皇岛有限公司 Perilla seed compound preparation and preparation method thereof
CN105362936A (en) * 2015-11-25 2016-03-02 天津天狮生物发展有限公司 Composition capable of assisting blood lipid reducing and preparation method of composition
CN105641509A (en) * 2016-01-14 2016-06-08 吕海峰 Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨培民: "《最新中成药手册》", 30 November 2014 *
犀文图书: "《血脂高了怎么吃》", 30 April 2015 *

Also Published As

Publication number Publication date
CN106890307B (en) 2018-07-10
WO2018171585A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CN108403882B (en) Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof
CN101007157A (en) Traditional Chinese medicine compound preparation for treating chronic cholecystitis
CN104436145B (en) It is a kind of to prevent and/or treatment allergic rhinitis and the pharmaceutical composition of allergic asthma
CN111714553A (en) A Chinese medicinal composition for treating new coronary pneumonia and/or influenza, and its preparation method
CN106266949A (en) A kind of compound Chinese medicinal preparation and its preparation method and application
CN102940709B (en) Medicine composition for treating gout
WO2020097963A1 (en) Traditional chinese medicine composition for treating hyperlipidemia
CN104435567A (en) Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout
CN106890307B (en) A kind of Chinese medicine composition with effect for reducing blood fat
CN104095940B (en) A kind of Chinese medicine composition for the treatment of gout
CN104547683B (en) A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof
CN102940747B (en) Medicine composition for treating gout
CN106075229A (en) A kind of Chinese medicinal composition preparation treating anemopyretic cold
CN102940850B (en) Medicine composition for treating gout
CN106581236A (en) Medicinal composition for promoting gastric motility, and preparation method and application thereof
CN102526509B (en) Medicine for treating hepatomegaly
CN106109594A (en) A kind of compositions treating headache and preparation method thereof
CN108143875B (en) Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof
CN107970310B (en) Traditional Chinese medicine composition for treating diabetic nephropathy
CN112755137B (en) Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof
CN114903939B (en) New medical application of Jingfeng preparation
CN112089783B (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity
CN108606996A (en) It is a kind of that there is the pharmaceutical composition for improving immune function
CN101732539B (en) Medicament for treating gynecological diseases and preparation method thereof
CN102133274A (en) Chinese medicinal composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant